STOCK TITAN

OnKure (OKUR) CEO Nicholas Saccomano awarded 330,000 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

OnKure Therapeutics, Inc. reported that President and CEO Nicholas A. Saccomano received a grant of employee stock options covering 330,000 shares of Class A Common Stock. The options have an exercise price of $4.07 per share and expire on March 31, 2036.

According to the filing, Saccomano holds 330,000 options following this grant, all as direct holdings. The award vests over time, with 1/48th of the option shares vesting on May 1, 2026 and monthly thereafter, contingent on his continued service with the company.

Positive

  • None.

Negative

  • None.
Insider Saccomano Nicholas A
Role President and CEO
Type Security Shares Price Value
Grant/Award Employee Stock Option (right to buy) 330,000 $0.00 --
Holdings After Transaction: Employee Stock Option (right to buy) — 330,000 shares (Direct)
Footnotes (1)
  1. [object Object]
Option grant size 330,000 options Employee stock option grant to CEO for Class A Common Stock
Exercise price $4.07 per share Exercise price of employee stock option grant
Expiration date March 31, 2036 Option expiration date for CEO grant
Post-grant derivative holdings 330,000 options Total options held following the reported transaction
Initial vesting date fraction 1/48th on May 1, 2026 First vesting installment of CEO option grant
Employee Stock Option financial
"security_title: "Employee Stock Option (right to buy)""
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
exercise price financial
"conversion_or_exercise_price: "4.0700" per share as the exercise price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"1/48th of the shares subject to the option shall vest on May 1, 2026"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Class A Common Stock financial
"underlying_security_title: "Class A Common Stock""
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Saccomano Nicholas A

(Last)(First)(Middle)
C/O ONKURE THERAPEUTICS, INC.
6707 WINCHESTER CIRCLE, SUITE 400

(Street)
BOULDER COLORADO 80301

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
OnKure Therapeutics, Inc. [ OKUR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$4.0704/01/2026A330,000 (1)03/31/2036Class A Common Stock330,000$0330,000D
Explanation of Responses:
1. 1/48th of the shares subject to the option shall vest on May 1, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
/s/ Rogan Nunn, by power of attorney04/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did OnKure Therapeutics (OKUR) disclose for Nicholas Saccomano?

OnKure Therapeutics disclosed that President and CEO Nicholas A. Saccomano received a grant of employee stock options for 330,000 shares of Class A Common Stock. These options were awarded as compensation and are not an open-market stock purchase or sale.

What are the key terms of Nicholas Saccomano’s new stock options at OnKure (OKUR)?

The granted employee stock options cover 330,000 underlying Class A Common Stock shares at an exercise price of $4.07 per share. They expire on March 31, 2036, giving Saccomano the right to buy shares at that price before expiration, subject to vesting.

How do Nicholas Saccomano’s OnKure (OKUR) options vest over time?

The filing states that 1/48th of the option shares will vest on May 1, 2026, with additional installments vesting each month thereafter. Vesting continues only if Saccomano remains a service provider to OnKure through each scheduled vesting date, making it time-based compensation.

How many options does Nicholas Saccomano hold after this OnKure (OKUR) grant?

After this grant, Saccomano holds 330,000 employee stock options directly, as reported in the filing. All these options relate to Class A Common Stock and reflect his total option position shown, indicating this award establishes his reported derivative holdings in the company.

Is Nicholas Saccomano’s OnKure (OKUR) Form 4 transaction a market buy or sell of shares?

No, the Form 4 describes a grant of employee stock options, not a market buy or sell of OnKure shares. The transaction code is “A” for a grant or award, meaning these options were issued as compensation rather than acquired or disposed of in open-market trading.